Sage Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$878K Hold
730
0.34% 65
2026
Q1
$673K Buy
730
+1
+0.1% +$1.01K 0.32% 71
2025
Q4
$785K Hold
729
0.36% 64
2025
Q3
$557K Hold
729
0.25% 81
2025
Q2
$568K Buy
729
+2
+0.3% +$1.55K 0.27% 77
2025
Q1
$601K Sell
727
-157
-18% -$131K 0.33% 69
2024
Q4
$682K Sell
884
-139
-14% -$115K 0.34% 63
2024
Q3
$907K Hold
1,023
0.44% 59
2024
Q2
$926K Sell
1,023
-64
-6% -$51.2K 0.49% 54
2024
Q1
$846K Hold
1,087
0.46% 60
2023
Q4
$633K Buy
+1,087
New +$634K 0.38% 67

Other funds holding LLY

Sage Capital Management's LLY Position: Q2 2026 in Review

Sage Capital Management held its Eli Lilly (LLY) position steady in Q2 2026 at 730 shares worth $878K. The position accounts for 0.34% of the portfolio, ranked #65.

Sage Capital Management first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. The position peaked at $926K in Q2 2024. 1,691 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Sage Capital Management held 730 shares of Eli Lilly worth $878K as of Q2 2026.
  • Sage Capital Management left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 0.34% of Sage Capital Management's portfolio in Q2 2026, its #65 holding.
  • Sage Capital Management first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • Sage Capital Management's Eli Lilly position peaked at $926K in Q2 2024.
  • 1,691 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Sage Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.